Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab

Asia-Pacific Journal of Clinical Oncology

Volumn 2, Issue 1, 2006, Pages 50-56

  Dawson, Sarah Jane ^a,b   Ranieri, Nadia F ^a   Snyder, Raymond D ^a   McLachlan, Sue Anne ^a   Burns, William I ^a   Newnham, Genni M ^a   Francis, Prudence A ^a   Dowling, Anthony J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Breast carcinoma; Central nervous system; HER 2; Metastases; Trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRANIOTOMY; CYTOREDUCTIVE SURGERY; GENE OVEREXPRESSION; HUMAN; HYPOTHESIS; LIVER METASTASIS; LUNG METASTASIS; METASTASIS POTENTIAL; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STEREOTAXIC SURGERY; TREATMENT OUTCOME;

EID: 33644666028     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2006.00036.x     Document Type: Article

References (17)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
2. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936-42.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
4. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44: 1913-8.
5. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349- 54.
6. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2005, July 15 [Epub ahead of print: 10.1016/j-breast.2005.04.017].
7. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97: 2972-7.
8. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004; 40: 379-82.
9. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-43.
10. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18: 2349-51.
11. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101: 810-16.
12. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650-5.
13. Engel J, Eckel R, Aydemir U et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 2003; 55: 1186-95.
14. Kirsch DG, Ledezma CJ, Mathews CS et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol, 2005: 23: 2114-6: Author reply 2116-7.
15. Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 2000; 21: 1064-6.
16. Lishner M, Feld R, Payne DG et al. Late neurological complications after prophylactic cranial irradiation in patients with small-cell lung cancer: The Toronto experience. J Clin Oncol 1990; 8: 215-21.
17. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-84.